Rahul S Dalal

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 33

Top Topics

Clostridium Difficile

Ulcerative Colitis

Patients With Inflammatory Bowel Disease

Top Venues

Inflammatory bowel diseases

The American journal of gastroenterology

Alimentary pharmacology & therapeutics

Digestive diseases and sciences

This page only lists publications with an associated author ORCID identifier.

Publications

Bente Mertz Nørgård, Caroline Thingholm Thorarinsson, Floor Dijkstra Zegers, Jens Kjeldsen, Rahul S Dalal, Ken Lund, Torben Knudsen
The use of opioids nine months after surgery for Crohn's disease - a nationwide cohort study. Alimentary pharmacology & therapeutics 60 (1) (2024)
Rahul S Dalal, Rachel W Winter, Sanchit Gupta, Gila F Sasson, Matthew J Hamilton, Jessica R Allegretti
Clinical Outcomes at 8-16 Weeks After Upadacitinib Initiation for Acute Severe Ulcerative Colitis: A Case Series in the United States. Inflammatory bowel diseases 30 (6) (2024)
Rahul S Dalal, Jessica R Allegretti
Reply: In Severe Inflammatory Bowel Disease, the Onset of Effectiveness of Biologics and Small Molecules Depends More on the Medication Than on the Diagnosis. Inflammatory bowel diseases (2024)
Rahul S Dalal
Limiting Opioid Use for Patients Who Are Hospitalized for Inflammatory Bowel Disease Exacerbations. Inflammatory bowel diseases (2024)
Rahul S Dalal, Jessica R Allegretti
Reply: Tofacitinib in Ulcerative Colitis: Beyond Biologics? Inflammatory bowel diseases 30 (3) (2024)
Rahul S Dalal, Govind Kallumkal, Heidy J Cabral, Edward L Barnes, Jessica R Allegretti
One-Year Comparative Effectiveness of Upadacitinib vs Tofacitinib for Ulcerative Colitis: A Multicenter Cohort Study. The American journal of gastroenterology (2024)
Bente Mertz Nørgård, Caroline Thingholm Thorarinsson, Floor Dijkstra Zegers, Jens Kjeldsen, Rahul S Dalal, Ken Lund, Torben Knudsen
The use of opioids nine months after surgery for Crohn's disease - a nationwide cohort study. Alimentary pharmacology & therapeutics 60 (1) (2024)
Bente Mertz Nørgård, Caroline Thingholm Thorarinsson, Floor Dijkstra Zegers, Jens Kjeldsen, Rahul S Dalal, Ken Lund, Torben Knudsen
The use of opioids nine months after surgery for Crohn's disease - a nationwide cohort study. Alimentary pharmacology & therapeutics 60 (1) (2024)
Rahul S Dalal, Govind Kallumkal, Heidy J Cabral, Edward L Barnes, Jessica R Allegretti
One-Year Comparative Effectiveness of Upadacitinib Versus Tofacitinib For Ulcerative Colitis: A Multicenter Cohort Study. The American journal of gastroenterology (2024)
Rahul S Dalal, Rachel W Winter, Sanchit Gupta, Gila F Sasson, Matthew J Hamilton, Jessica R Allegretti
Clinical Outcomes at 8-16 Weeks After Upadacitinib Initiation for Acute Severe Ulcerative Colitis: A Case Series in the United States. Inflammatory bowel diseases (2024)
Jessica R Allegretti, Jordan E Axelrad, Rahul S Dalal, Colleen R Kelly, Ari Grinspan, Monika Fischer
Outcomes After Fecal Microbiota Transplantation in Combination With Bezlotoxumab for Inflammatory Bowel Disease and Recurrent Clostridioides difficile Infection. The American journal of gastroenterology 119 (7) (2024)
Rahul S Dalal, Lindsay M Clarke, Alex Carlin, Heidy Cabral, Jessica R Allegretti
Real-World Comparison of Effectiveness, Treatment Persistence, and Safety of First-Line Advanced Therapies at 1 Year for Ulcerative Proctitis. Inflammatory bowel diseases (2024)
Jessica R Allegretti, Jordan E Axelrad, Rahul S Dalal, Colleen R Kelly, Ari Grinspan, Monika Fischer
Outcomes After Fecal Microbiota Transplantation in Combination With Bezlotoxumab for Inflammatory Bowel Disease and Recurrent Clostridioides difficile Infection. The American journal of gastroenterology (2024)
Jessica R Allegretti, Jordan E Axelrad, Rahul S Dalal, Colleen R Kelly, Ari Grinspan, Monika Fischer
Outcomes after Fecal Microbiota Transplantation in combination with Bezlotoxumab for Inflammatory Bowel Disease and Recurrent C . difficile Infection. The American journal of gastroenterology (2024)
Jessica R Allegretti, Jordan E Axelrad, Rahul S Dalal, Colleen R Kelly, Ari Grinspan, Monika Fischer
Outcomes after Fecal Microbiota Transplantation in combination with Bezlotoxumab for Inflammatory Bowel Disease and Recurrent C. difficile Infection. The American journal of gastroenterology (2024)
Jessica R Allegretti, Jordan E Axelrad, Rahul S Dalal, Colleen R Kelly, Ari Grinspan, Monika Fischer
Outcomes After Fecal Microbiota Transplantation in Combination With Bezlotoxumab for Inflammatory Bowel Disease and Recurrent Clostridioides difficile Infection. The American journal of gastroenterology 119 (7) (2024)
Jessica R Allegretti, Jordan E Axelrad, Rahul S Dalal, Colleen R Kelly, Ari Grinspan, Monika Fischer
Outcomes After Fecal Microbiota Transplantation in Combination With Bezlotoxumab for Inflammatory Bowel Disease and Recurrent Clostridioides difficile Infection. The American journal of gastroenterology 119 (7) (2024)
Bente Mertz Nørgård, Caroline Thingholm Thorarinsson, Floor Dijkstra Zegers, Jens Kjeldsen, Rahul S Dalal, Ken Lund, Torben Knudsen
The use of opioids nine months after surgery for Crohn's disease - a nationwide cohort study. Alimentary pharmacology & therapeutics (2024)
Rahul S Dalal, Rachel W Winter, Sanchit Gupta, Gila F Sasson, Matthew J Hamilton, Jessica R Allegretti
Clinical Outcomes at 8-16 Weeks After Upadacitinib Initiation for Acute Severe Ulcerative Colitis: A Case Series in the United States. Inflammatory bowel diseases 30 (6) (2024)
Rahul S Dalal, Joerg Ermann, Alexander Carlin, Jennifer Mitri, Jessica R Allegretti
Activity of axial spondyloarthritis after one year of anti-tumor necrosis factor therapy among patients with inflammatory bowel diseases. Clinical rheumatology (2023)
Rahul S Dalal, Govind Kallumkal, Heidy J Cabral, Salam Bachour, Edward L Barnes, Jessica R Allegretti
Clinical and Endoscopic Outcomes After Upadacitinib Induction for Ulcerative Colitis: A Multicenter Retrospective Cohort Study. Inflammatory bowel diseases (2023)
Rahul S Dalal, Esther Baranov, Jessica Li, Xuefei Hong, Joshua Korzenik, Matthew Hamilton, Gila Sasson
Small Cells, Big Problems: Small Cell Carcinoma of the Rectal Cuff After Ileal-Pouch Anal Anastomosis in a Patient with Ulcerative Colitis. Digestive diseases and sciences (2023)
Rahul S Dalal, Puza P Sharma, Kanwal Bains, Jordan C Pruce, Jessica R Allegretti
1-Year Comparison of Clinical and Endoscopic Outcomes of Tofacitinib vs Vedolizumab for Ulcerative Colitis After Anti-Tumor Necrosis Factor Failure: A Real-World Cohort Study in the United States. Inflammatory bowel diseases (2023)
Rahul S Dalal, Jessica R Allegretti
Reply: Tofacitinib in Ulcerative Colitis: Beyond Biologics? Inflammatory bowel diseases (2023)
Rahul S Dalal, Puza P Sharma, Kanwal Bains, Jordan C Pruce, Jessica R Allegretti
1-Year Comparative Effectiveness of Tofacitinib vs Ustekinumab for Patients With Ulcerative Colitis and Prior Antitumor Necrosis Factor Failure. Inflammatory bowel diseases (2023)
Rahul S Dalal, Puza P Sharma, Kanwal Bains, Jordan C Pruce, Jessica R Allegretti
Clinical and Endoscopic Outcomes Through 78 Weeks of Tofacitinib Therapy for Ulcerative Colitis in a US Cohort. Inflammatory bowel diseases (2023)
Rahul S Dalal, Bente Mertz Nørgård, Floor Dijkstra Zegers, Jens Kjeldsen, Sonia Friedman, Jessica R Allegretti, Ken Lund
Older Adult-Onset of Inflammatory Bowel Diseases is Associated With Higher Utilization of Analgesics: A Nationwide Cohort Study. The American journal of gastroenterology (2023)
Rahul S Dalal, Ken Lund, Floor D Zegers, Sonia Friedman, Jessica R Allegretti, Bente Mertz Nørgård
Use of Tramadol vs Traditional Opioids and Adverse Outcomes in Patients with Inflammatory Bowel Disease: A Danish Nationwide Cohort Study. Inflammatory bowel diseases (2023)
Rahul S Dalal, Jordan C Pruce, Jessica R Allegretti
Long-Term Outcomes After Ustekinumab Dose Intensification for Inflammatory Bowel Diseases. Inflammatory bowel diseases (2022)
Rahul S Dalal, Kanwal Bains, Jenna Marcus, Emma L McClure, Jessica R Allegretti
Tofacitinib for the Treatment of Pouch-Related Disorders: A Case Series. Inflammatory bowel diseases 28 (11) (2022)
Rahul S Dalal, Jennifer Mitri, Hannah Goodrick, Jessica R Allegretti
Real-World Comparison of Tofacitinib vs Ustekinumab Among Bio-Exposed Patients With Ulcerative Colitis: A Propensity Score Analysis. Inflammatory bowel diseases 27 (10) (2022)
Rahul S Dalal, Sanchit Gupta, Hannah Goodrick, Jennifer Mitri, Jessica R Allegretti
Outcomes of Standard and Intensified Dosing of Ustekinumab for Chronic Pouch Disorders. Inflammatory bowel diseases (2021)
Rahul S Dalal, Jessica R Allegretti
Ustekinumab Dose Optimization in Crohn Disease: One Size Does Not Fit All. Inflammatory bowel diseases 27 (6) (2021)